EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Sentinel Lymph Node Biopsy in Clinically Node‐Negative Merkel Cell Carcinoma: An Update of the Westmead Hospital Experience

Julie Ahn iD, Julie R Howle, Michael J Veness iD

ANZ Journal of Surgery · 2026-10 · 96 (10) · 2883-2888

DOI: 10.1111/ans.70692 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ANZ Journal of Surgery, online erschienen am 16.04.2026. Verfasst von Julie Ahn und 2 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Network, Western Sydney Local Health District, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, Sentinel Lymph Node Biopsy, Skin Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous neuroendocrine malignancy with a high risk of nodal metastasis. Sentinel lymph node biopsy (SLNB) is used to stage clinically node‐negative disease and to guide adjuvant therapy decisions. This study updates the Westmead Hospital experience with an expanded cohort and extended follow‐up.

Methods

Patients with clinically node‐negative MCC who underwent SLNB between 1998 and 2024 were identified from an institutional database. Demographic, tumour, treatment and outcome data were reviewed.

Results

A total of 75 patients (57 men, 18 women; median age 74 years) underwent SLNB. A total of 28 (37%) had a positive SLNB and 47 (63%) a negative SLNB. Seven patients with a negative SLNB developed nodal recurrence, for a false‐negative rate of 20%. Among patients with head and neck primaries, the false‐negative rate was 12% (3/31). Overall recurrence occurred in 11 of 47 (23%) SLNB‐negative and 11 of 28 (39%) SLNB‐positive patients ( p = 0.23). Distant recurrence was more frequent after a positive SLNB (18% vs. 6%). Overall survival did not differ significantly by SLNB status ( p = 0.11).

Conclusion

MCC demonstrates a high rate of subclinical nodal metastases, with a SLNB positivity rate of nearly 40% in our series. These findings support the use of SLNB in the management of clinically node‐negative MCC to improve staging accuracy, prognostication and guide management decisions, with an acceptable false‐negative rate under close surveillance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Merkel CellSentinel Lymph Node BiopsySkin NeoplasmsHumansFemaleMaleAgedAged, 80 and overMiddle AgedRetrospective StudiesNeoplasm Recurrence, LocalLymphatic MetastasisNeoplasm StagingFalse Negative Reactions

Stichwörter der Autor:innen

Merkel cell carcinomaradiotherapysentinel lymph node biopsy

Autor:innen und Institutionen

  • Radiation Oncology Network, Western Sydney Local Health District, Sydney, New South Wales, Australia.
  • Department of Surgical Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
  • Sydney Medical School, Sydney University, Sydney, New South Wales, Australia.

ORCID-Profile: Julie Ahn, Michael J Veness

Zitieren

APA

Ahn, J., Howle, J. R., & Veness, M. J. (2026). Sentinel Lymph Node Biopsy in Clinically Node‐Negative Merkel Cell Carcinoma: An Update of the Westmead Hospital Experience. ANZ Journal of Surgery, 96(10), 2883-2888. https://doi.org/10.1111/ans.70692

Vancouver

Ahn J, Howle JR, Veness MJ. Sentinel Lymph Node Biopsy in Clinically Node‐Negative Merkel Cell Carcinoma: An Update of the Westmead Hospital Experience. ANZ Journal of Surgery. 2026;96(10):2883-2888. doi:10.1111/ans.70692

BibTeX
@article{Ahn2026,
  author = {Ahn, Julie and Howle, Julie R and Veness, Michael J},
  title = {Sentinel Lymph Node Biopsy in Clinically Node‐Negative Merkel Cell Carcinoma: An Update of the Westmead Hospital Experience},
  journal = {ANZ Journal of Surgery},
  year = {2026},
  volume = {96},
  number = {10},
  pages = {2883--2888},
  doi = {10.1111/ans.70692}
}
Kostenlos starten →